Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and raremore
Cambridge, United States of AmericaPharmaceuticals & Biotech
Manufacturer of power production infrastructure products intended to serve commercial and residential. The company offers renewable power generation products including wind turbines and generates energy.
Provider of marketing and communication services based in Stockport, United Kingdom. The company provides print management and production, content creation, data management and card personalization, business intelligence and branding services, thereby helping brands talk to their customers.
